Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling

Oncogene

Volumn 27, Issue 28, 2008, Pages 3923-3934

  Tsuchida, R ^a   Das, ^a,b   Yeger, H ^a,b   Koren, G ^b   Shibuya, M ^c   Thorner, P S ^a,b   Baruchel, S ^a,b,d   Malkin, D ^a,b,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cisplatin; Osteosarcoma; Tumorigenic SP; VEGF Flt1 autocrine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BMI1 PROTEIN; CISPLATIN; DOXORUBICIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OCTAMER TRANSCRIPTION FACTOR 4; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER SURVIVAL; CELL POPULATION; CLONOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; OSTEOSARCOMA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 43249098495     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.38     Document Type: Article

References (40)

1. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P et al. (2003). Flt-1-dependent survival characterizes the epithelial- mesenchymal transition of colonic organoids. Curr Biol 13: 1721-1727.
2. Behrends M, Schulz R, Post H, Alexandrov A, Belosjorow S, Michel MC et al. (2000). Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. Am J Physiol Heart Circ Physiol 279: H1111-H1119.
3. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. (2001). Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97: 1427-1434.
4. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL et al. (2007). Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117: 1305-1313.
5. Brozovic A, Osmak M. (2007). Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1-16.
6. Cara S, Tannock IF. (2001). Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 12: 23-27.
7. Cole S, Tannock IF. (2004). Drug Resistance, 4th edn. McGraw-Hill: Toronto, 390 pp.
8. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. (2003). Stem cell mobilization. Hematology Am Soc Hematol Educ Program, 419-437.
9. Das B, Tsuchida R, Malkin D, Baruchel S, Yeger H. (2007). Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side-population fraction. Stem Cells (under review).
10. Das B, Yeger H, Baruchel H, Freedman M, Koren G, Baruchel S. (2003). In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. Implications in cancer chemotherapy. Eur J Cancer 39: 2556-2565.
11. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, Thorner PS et al. (2005). A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65: 7267-7275.
12. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106: 511-521.
13. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676.
14. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
15. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N et al. (1998). Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725.
16. Gasparini G, Harris AL. (1995). Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13: 765-782.
17. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D. (2005). Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 24: 8025-8037.
18. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. (2005). A distinct 'side population' of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 4: 203-205.
19. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. (2004). A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233.
20. Ho MM, Ng AV, Lam S, Hung JY. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833.
21. Kim JJ, Tannock IF. (2005). Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-525.
22. Kondo T, Setoguchi T, Taga T. (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786.
23. Lin X, Costa M. (1994). Transformation of human osteoblasts to anchorage-independent growth by insoluble nickel particles. Environ Health Perspect 102(Suppl 3): 289-292.
24. McAllister RM, Gardner MB, Greene AE, Bradt C, Nichols WW, Landing BH. (1971). Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27: 397-402.
25. Mercurio AM, Bachelder RE, Bates RC, Chung J. (2004). Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. Semin Cancer Biol 14: 115-122.
26. Miller AC, Blakely WF, Livengood D, Whittaker T, Xu J, Ejnik JW et al. (1998). Transformation of human osteoblast cells to the tumorigenic phenotype by depleted uranium-uranyl chloride. Environ Health Perspect 106: 465-471.
27. Miller AC, Mog S, McKinney L, Luo L, Allen J, Xu J et al. (2001). Neoplastic transformation of human osteoblast cells to the tumorigenic phenotype by heavy metal-tungsten alloy particles: induction of genotoxic effects. Carcinogenesis 22: 115-125.
28. Miura K, Uniyal S, Leabu M, Oravecz T, Chakrabarti S, Morris VL et al. (2005). Chemokine receptor CXCR4-beta1 integrin axis mediates tumorigenesis of osteosarcoma HOS cells. Biochem Cell Biol 83: 36-48.
29. Montanaro F, Liadaki K, Schienda J, Flint A, Gussoni E, Kunkel LM. (2004). Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters. Exp Cell Res 298: 144-154.
30. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. (2005). Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219.
31. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. (2007). Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res 67: 6796-6805.
32. Qi L, Robinson WA, Brady BM, Glode LM. (2003). Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 23: 3917-3922.
33. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. (2006). Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 5: 1799-1807.
34. Richman CM, Weiner RS, Yankee RA. (1976). Increase in circulating stem cells following chemotherapy in man. Blood 47: 1031-1039.
35. Salnikow K, An WG, Melillo G, Blagosklonny MV, Costa M. (1999). Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors. Carcinogenesis 20: 1819-1823.
36. Setoguchi T, Taga T, Kondo T. (2004). Cancer stem cells persist in many cancer cell lines. Cell Cycle 3: 414-415.
37. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. (2001). Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159: 651-659.
38. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. (2004). Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 66: 129-138.
39. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al. (2001). Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193: 468-475.
40. Woessmann W, Chen X, Borkhardt A. (2002). Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol 50: 397-404.